Christopher T. Ritchlin

Jul 11, 2024 | healio.com | Justin Cooper |Shenaz Bagha |Christopher T. Ritchlin

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients with active PsA met disease control endpoints with guselkumab at 100 weeks. Across subgroups, 50% to 70% had complete skin clearance, while 65% to 85% had enthesitis/dactylitis resolution.

May 21, 2024 | acrjournals.onlinelibrary.wiley.com | Oliver FitzGerald |Dafna D Gladman |Philip Mease |Christopher T. Ritchlin

Supporting Information Filename Description art42921-sup-0001-Disclosureform.pdfPDF document, 518.9 KB Disclosure Form art42921-sup-0002-Supinfo.docxWord 2007 document , 354 KB Appendix S1: Supporting Information

Nov 1, 2023 | healio.com | Sara Kellner |Shenaz Bagha |Christopher T. Ritchlin

You've successfully added Rheumatology: Psoriatic Arthritis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Bimekizumab demonstrated sustained efficacy between 16 and 52 weeks of treatment in patients with psoriatic arthritis.

Oct 12, 2023 | ard.bmj.com | Christopher T. Ritchlin |Laura Coates |Iain B McInnes |Philip Mease

Up to Week 52, 555/702 (79.1%; EAIR/100 PY: 222.5) patients reported ≥1 TEAE while receiving BKZ treatment, including patients who switched from PBO to BKZ at Week 16; 113/140 (80.7%; EAIR/100 PY: 209.4) ADA-treated patients reported ≥1 TEAE to Week 52. Up to Week 52, 46 (6.6%; EAIR/100 PY: 7.9) patients receiving BKZ treatment and 10 (7.1%; EAIR/100 PY:‍ 7.5) patients receiving ADA treatment reported an SAE.

Sep 11, 2023 | ard.bmj.com | Christopher T. Ritchlin |Laura Coates |Iain B McInnes |Philip Mease

DiscussionBE OPTIMAL demonstrated long-term efficacy of BKZ up to Week 52 in patients with active PsA who were bDMARD-naïve across a range of PsA domains, including joints, skin, enthesitis, dactylitis and nails, as well as the inhibition of structural progression. Improvements in efficacy as assessed by stringent outcome measures were sustained from Week 16 to Week 52 with BKZ treatment, with a low rate of patient drop-out. Furthermore, safety was as expected with no new safety signals observed.